HLS Therapeutics (TSE:HLS - Get Free Report) will release its earnings data before the market opens on Thursday, November 7th. Analysts expect HLS Therapeutics to post earnings of C($0.19) per share for the quarter.
HLS Therapeutics (TSE:HLS - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported C($0.25) earnings per share for the quarter, meeting the consensus estimate of C($0.25). HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. The company had revenue of C$19.87 million during the quarter, compared to analyst estimates of C$19.25 million.
HLS Therapeutics Stock Performance
Shares of HLS Therapeutics stock traded down C$0.06 on Thursday, reaching C$3.34. 391,300 shares of the company traded hands, compared to its average volume of 26,643. HLS Therapeutics has a 52 week low of C$3.00 and a 52 week high of C$5.48. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01. The company has a 50 day moving average of C$3.50 and a 200 day moving average of C$3.66. The firm has a market capitalization of C$106.18 million, a PE ratio of -3.38 and a beta of 1.07.
Wall Street Analyst Weigh In
Separately, Stifel Nicolaus dropped their price target on HLS Therapeutics from C$3.75 to C$3.25 in a research report on Tuesday, August 13th.
Read Our Latest Stock Report on HLS
HLS Therapeutics Company Profile
(
Get Free Report)
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
See Also
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
